Company: ATRA
Filing Date: 2025-03-07
Form Type: 10-K
Source: 0000950170-25-035507
Chunk: 193

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-03-07
Form: 10-K
Item: Item 1B
Chunk 193
---
 
    $
    (85,191
    )
     
    $
    (274,263
    )

    Basic and diluted net loss per common share
     
    $
    (11.41
    )
     
    $
    (65.19
    )

    Basic and diluted weighted-average shares outstanding

    7,488

    4,236

 See accompanying notes to the consolidated financial statements.

100

Atara Biotherapeutics, Inc. 

Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

(In thousands)

    Accumulated

    Common

    Additional

    Other

    Total

    Stock

    Paid-in

    Comprehensive

    Accumulated

    Stockholders’

    Shares

    Amount

    Capital

    (Loss) Income

    Deficit

    Equity (Deficit)

    Balance as of January, 1 2023

    3,837

    —

    1,821,731

    (2,067
    )

    (1,693,024
    )

    126,640

    Issuance of common stock through ATM facilities, net of   commissions and offering costs of $351

    122

    —

    2,172

    —

    —

    2,172

    Exercise of pre-funded warrants

    116

    —

    —

    —

    —

    -

    RSU settlements, net of shares withheld

    147

    —

    (94
    )

    —

    —

    (94
    )

    Issuance of common stock pursuant to employee stock awards

    36

    —

    928

    —

    —

    928

    Stock-based compensation expense

    —

    —

    45,386

    —

    —

    45,386

    Net loss

    —

    —

    —

    —

    (276,126
    )

    (276,126
    )

    Unrealized gain (loss) on available-for-sale securities

    —

    —

    —

    1,863

    —

    1,863

    Balance as of December 31, 2023

    4,258

    —

    1,870,123

    (204
    )

    (1,969,150
    )

    (99,231
    )

    Issuance of common stock and pre-funded warrants to purchase common stock through